Double-Blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis.

Trial Profile

Double-Blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 Apr 2012

At a glance

  • Drugs Rabeprazole (Primary)
  • Indications Reflux oesophagitis
  • Focus Registrational; Therapeutic Use
  • Acronyms TWICE
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 20 Mar 2012 Results published in the American Journal of Gastroenterology.
    • 10 May 2011 Results presented at the Digestive Disease Week 2011.
    • 21 Dec 2010 Twice daily administration of 10mg or 20mg doses approved in Japan based on the results of this trial, according to an Eisai Co media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top